期刊文献+

联合用药后凝固酶阴性葡萄球菌体外抗菌活性分析

Analysis in vitro antibacrerial activity of Coagulase negative Staphyeococcus Post combining antimicrabial agents
下载PDF
导出
摘要 目的了解常用抗菌药物及联合药物对医院内感染凝固酶阴性葡萄球菌(CNS)的体外抗菌活性。方法常规方法培养细菌,用VITEK全自动微生物分析仪鉴定到种。MIC测定采用琼脂干板稀释方法,按照CLSI规定的标准进行。结果50株凝固酶阴性葡萄球菌对万古霉素、左氧氟沙星、阿米卡星、头孢脞啉的MIC90分别为2.0、16.0、8.0、64.0mg/L。万古霉素与左氧氟沙星、阿米卡星、头孢唑啉联合用药的MIC90分别为2.0、1.0、1.0mg/L,左氧氟沙星与阿米卡星、头孢唑啉联合用药的MIC90为2.0、8.0mg/L。结论医院内感染凝固酶阴性葡萄球菌的发生率及耐药性已越来越高,临床应根据病原菌感染的种类和细菌实验室药敏结果,结合临床经验用药的药物疗效正确使用抗菌药物。 Objective To understand in vitro antibacterial activity of rourine antimicrobial agents and combing-drug against coagulase negative staphylococcus(CNS) in nosocomial infeerion.Methods The isolates were cultured by routine procedure and identified by VITEK microhe automatic analysis instrument.MIC detection used agar plate dilution methods according to the standard of CLS1.Results The MIC90 of vancomycin(VAD)、Levofloxacin(LVF)、 Amikacin(AMK)、Cefazolin(CFZ) were2.0、16.0、8.0、64.0mg/L against 50 strains CNS respertively.VAN combried with LVF、AMK、CFZ-S MIC90 were 2.0、1.0、1.0mg/L respectively,LVF combined with AMK and CFZ-S MIC90 were 2.0 and 8.0mg/l respectively.Conclusion The occurred rate and drus resistance of CNC are more and more higher in nosoeomial infection.Clinic should use antimicrobial agents properly according to the pathogen spices and the results of drug suscepribility test and combine drug treatment effect with experienced using drug.
出处 《医学检验与临床》 2007年第5期30-31,共2页 Medical Laboratory Science and Clinics
关键词 凝固酶阴性葡萄球菌 抗菌药物 最低抑菌浓度(MIC) 联合用药 Coagulase negative staphylococcus Anrimicrobial agents Minimum inhibitory concenh'afion(MIC) Combination of drug
  • 相关文献

参考文献1

二级参考文献9

  • 1Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing :practical aspects and current challenges.Clin Microbiol Rev,2001,14:643-658.
  • 2Verweij PE, Van den Bergh MF, Rath PM, et al. Invasive aspergillosisi caused by aspergillus ustus:case report and review.Clin Microbiol,1999,37:1606-1609.
  • 3Moore CB,Walls CM,Denning DW.In vitro activities of terbinafine against aspergillus species in comparison with those of itraconazole and amphotericin B.Antimicrob Agents Chemother,2001,45:1882-1885.
  • 4Te Dorsthorst DT,Verweij PE,Meis JF,et al.Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole -susceptible and resistant aspergillus fumigatus isolates.Antimicrob Agents Chemother,2002, 46:702-707.
  • 5Ryder NS, Leitner L. Synergistic interaction of terbinaflne with triazoles or amphotericin B against Aspergillus species.Med Mycol,2001,39:91-95.
  • 6Barchiesi F, Falconi DiFrancesco L, Scalise G, et al. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoes.Antimicrob Agents Chemother, 1997,41:1812-1814.
  • 7Kontoyiannis P, Lewis RE, Sagar N, et al. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus:an E-test -based strategy .Antimicrob Agents Chemother ,2000,44:2915-2918.
  • 8Mosquera J, Sharp A, Moore CB, et al. In vitro interaction of terbinafine with itraconazole, fluconazole ,amphotericin B and 5-flucytosine against Aspergillus spp.Antimicrob Chemother , 2002,50 : 189-194.
  • 9Nguyen MH, Barchiesi F,McGough DA, et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var neofomans.Antimicrob Agents Chemother , 1995,39 :1691-1695.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部